Alpha DNA Investment Management’s Tesla TSLA Stock Holding History

Alpha DNA Investment Management’s Portfolio TSLA Stock Details TSLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,114	Closed	-$384K	–	204
2022 Q4	$384K	Buy	+3,114	New	+$590K	0.14%	142
2021 Q2	–	Sell	-18	Closed	-$4K	–	612
2021 Q1	$4K	Buy	+18	New	+$4.52K	﹤0.01%	425

Other funds holding TSLA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Alpha DNA Investment Management's TSLA Position: Q1 2023 in Review

Alpha DNA Investment Management sold out of Tesla (TSLA) in Q1 2023, closing a stake of 3,114 shares — an estimated $384K sold.

Alpha DNA Investment Management first reported a position in TSLA in Q1 2021 and held it in 2 quarters. The position peaked at $384K in Q4 2022. 2,715 funds tracked by Wall St. Rank hold TSLA as of Q1 2023.

Alpha DNA Investment Management reported no remaining Tesla position as of Q1 2023 after selling out during the quarter.
Alpha DNA Investment Management sold 3,114 Tesla shares in Q1 2023, an estimated $384K.
Alpha DNA Investment Management first reported a position in Tesla in Q1 2021 and held it in 2 quarters.
Alpha DNA Investment Management's Tesla position peaked at $384K in Q4 2022.
2,715 funds tracked by Wall St. Rank held Tesla as of Q1 2023.

Based on Alpha DNA Investment Management's 13F filing for Q1 2023, filed 5 May 2023.